Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

121-140 of 847 trials

Pulmonary Arterial Hypertension: Seralutinib Inhalation Study

We are studying whether inhaling seralutinib helps improve exercise capacity in people with pulmonary arterial hypertension. The trial also looks at safety and other health benefits compared to a placebo.

Pulmonary Arterial Hypertension1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementCardiologyPulmonology

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

Breast Cancer-Related Lymphedema: Topical Tacrolimus Study

We are investigating whether a topical ointment can reduce swelling in patients with breast cancer-related lymphedema. This study compares the ointment to a placebo to see if it improves symptoms and quality of life.

Lymphedema1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Standard Medicines Partially RemoteInternal MedicineOncology

Systemic Lupus Erythematosus: Upadacitinib Study

We are investigating whether the oral medication upadacitinib can improve symptoms in adults with moderate to severe systemic lupus erythematosus. The study will also monitor its safety over time compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Hidradenitis Suppurativa: Upadacitinib Study

We are testing Upadacitinib in adults and adolescents with moderate to severe Hidradenitis Suppurativa who haven't responded to other treatments. The goal is to see if it is more effective and safe than a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteDermatology

Chronic Cutaneous Lupus Erythematosus: Anifrolumab Study

We are investigating whether anifrolumab can improve skin symptoms in adults with chronic cutaneous lupus erythematosus who haven't responded to other treatments. The study will compare its effects to a placebo over 24 weeks.

Cutaneous Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteDermatologyRheumatology

Advanced Breast Cancer: Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib

We are studying two treatment combinations for men and women with advanced breast cancer and an ESR1 mutation. The goal is to see which combination helps patients live longer without disease progression.

Metastatic Breast Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Relatlimab and Nivolumab for Young Lymphoma Patients

We are studying a combination of two medications for children and young adults with recurrent or hard-to-treat Hodgkin and Non-Hodgkin lymphoma. The goal is to understand their safety and how well they may work.

Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteOncologyPediatrics

Gastroparesis: Tradipitant Safety Study

We are evaluating the safety of a new medication, tradipitant, for patients with gastroparesis. The study also looks at how well it may help reduce symptoms and improve quality of life.

Gastroparesis3-6 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteEndocrinologyGastroenterology

Mucopolysaccharidosis Type II: DNL310 Treatment Study

We are investigating the long-term safety and effects of DNL310 in patients with MPS II. This study looks at how well the treatment works for cognitive and physical development.

Hunter's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyNeurology

Bimekizumab for Children with Moderate to Severe Plaque Psoriasis

We are studying how well bimekizumab works compared to ustekinumab in children and teens aged 6 to under 18 with moderate to severe plaque psoriasis. The trial will also look at safety and quality of life improvements.

Plaque PsoriasisConfirmation phase (III)Post-Trial Drug Access Standard MedicinesAllergologyDermatology

Growth Hormone Deficiency: LUM-201 Treatment Study

We are monitoring the long-term safety of LUM-201 in children with idiopathic growth hormone deficiency. This study also looks at how the treatment affects growth and related health markers.

Idiopathic Growth Hormone Deficiency>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesEndocrinologyPediatrics

Guselkumab for Crohn's Disease Healing

We are studying whether guselkumab can help heal the intestinal wall in patients with Crohn's disease. This research aims to find out how effective it is over 48 weeks.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncologyPediatrics

Primary Biliary Cholangitis: Bezafibrate Treatments

We are studying the effects of two doses of bezafibrate in patients with primary biliary cholangitis who aren't responding well to current therapy. The goal is to see if these treatments can improve symptoms and liver health.

Primary Biliary Cholangitis>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Standard MedicinesGastroenterologyHepatology

Hunter Syndrome: Long-Term Safety of Idursulfase-IT and Elaprase®

We are studying the long-term safety of a treatment combining intrathecal idursulfase-IT and intravenous Elaprase® for individuals with Hunter syndrome and cognitive impairment. This research aims to ensure the safety of these therapies over time.

Hunter's SyndromeConfirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesHematologyInternal MedicineNeurology

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineOrthopedics and Traumatology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementNeurologyPsychiatry

Nipocalimab for Generalized Myasthenia Gravis

We are studying whether nipocalimab IV infusions can help adults with generalized myasthenia gravis perform daily activities better than a placebo. This research aims to assess its effectiveness and safety.

Myasthenia Gravis6-12 monthsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Search Clinical Trials in the European Union